Vivo Bio Tech reported a net loss of Rs 1.71 crore for FY26 compared to a profit of Rs 7.28 crore in the previous year, citing a major deferred tax charge and heavy capital spending. While income grew to Rs 53.78 crore and the firm added 30 new clients, its current ratio and debt-service coverage ratio have weakened. The company is currently in an intensive investment phase following the launch of a new large-animal facility.
Vivo Bio Tech FY26 Results: Loss Reported Amid Scaling
Net loss of Rs 1.71 crore vs. Rs 7.28 crore profit; Total income up to Rs 53.78 crore.
Reader Takeaway: Operational capacity is expanding significantly, but debt servicing and liquidity ratios require immediate management focus.
What just happened
Vivo Bio Tech concluded FY 2025-26 with a net loss of Rs 1.71 crore, shifting from a profitable position in FY 2024-25. The company’s total income rose to Rs 53.78 crore from Rs 51.48 crore in the previous year. Management identified a one-time deferred tax charge of Rs 5.71 crore as the primary driver behind the swing to red ink.
Why this matters
The company is currently in an aggressive growth phase, commissioning a new NGCMA GLP-certified large-animal facility dedicated to dog studies. While this expansion allows the company to bid for higher-value regulated contracts, the heavy investment cycle has pressured cash flows, resulting in a debt service coverage ratio of 0.83x, down from 1.38x in the prior year.
Operations and Business Update
Vivo Bio Tech added over 30 new clients during the fiscal year, including contracts with notable firms like NATCO, Dabur, and Lab4Life totaling Rs 19.83 crore. The firm also introduced advanced services including safety pharmacology and cell-line based efficacy studies to diversify its revenue streams.
Risks to watch
Liquidity is a primary concern for investors. The current ratio has dipped to 0.94x, meaning current liabilities exceed current assets. Management noted that delays in debt remittances were linked to temporary cash-flow mismatches, and the ability to stabilize these ratios will be vital for shareholder confidence in the coming quarters.
What to track next
Investors should monitor the utilization rates of the new LC-MS/MS platforms and the large-animal facility. The speed at which these assets translate into high-margin revenue will determine whether the company can normalize its debt-service profile and return to consistent profitability in FY 2026-27.